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Cypate-octreote peptide analogue conjugate (Cytate) was investigated as a prostate cancer receptor-
targeted contrast agent. The absorption and fluorescence spectra of Cytate were ranged in the near-
infrared “tissue optical window.” Time-resolved investigation of polarization-dependent fluorescence
emitted from Cytate in solution as well as in cancerous and normal prostate tissues was conducted.
Polarization preservation characteristics of Cytate in solution and tissues were studied. Fluorescence
intensity emitted from the Cytate-stained cancerous prostate tissue was found to be much stronger than
that from the Cytate-stained normal prostate tissue, indicating more Cytate uptake in the former tis-
sue type. The polarization anisotropy of Cytate contained in cancerous prostate tissue was found to be
larger than that in the normal prostate tissue, indicating a larger degree of polarization preservation in
Cytate-stained cancerous tissue. The temporal profiles of fluorescence from Cytate solution and from
Cytate-stained prostate tissue were fitted using a time-dependent fluorescence depolarization model.
The photoluminescence imaging of Cytate-stained cancerous and normal prostate tissues was accom-
plished, showing the potential of Cytate as a fluorescence marker for prostate cancer detection.
© 2008 Optical Society of America
OCIS codes: 300.6280, 110.3080.
1. Introduction
Prostate cancer was projected to account for ∼29% of
all cancer incidences in men, exceeding lung and
bronchus cancer in the US, and to cause more than
27000 deaths in 2007 [1]. Currently prostate cancer
diagnosis is based on digital rectal examination
(DRE), blood prostate specific antigen (PSA) test,
and the trans-rectal ultrasound (TRUS) imaging
[2]. While TRUS is no longer considered as a first-
line screening test for prostate cancer because of its
poor spatial resolution and contrast [3], DRE has a
reported sensitivity of as low as 18%–22% in asymp-
tomatic men [2]. PSA has limited specificity, and the
reported positive predictive value of PSA in asymp-
tomatic men is 28%–35% [2]. The confirmation of
prostate cancer requires a needle biopsy of the pros-
tate. In the biopsy, a number of cores of prostate tis-
sue are taken out with a thin needle guided into
selectedregions of the prostate with an ultrasound
probe. Because of poor spatial resolution and limited
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accuracy of these currently available methods, and
the invasive nature of needle biopsy, there is a need
to develop a noninvasive technique for early detec-
tion of prostate cancer with higher accuracy and
resolution.
Fluorescence spectroscopy was used as a novel tool
for detection of cancer by Alfano and his group [4] in
the 1980s. The work was extended to differentiate
human malignant breast tissues from benign and
normal tissue types using UV excitation [5]. Further
work on breast tissues and atherosclerotic arteries
showed how time-resolved fluorescence could provide
information not available from steady state spectral
analysis alone [6]. Several groups have investigated
various promising approaches using optical spectro-
scopy [7] and imaging [8] with high sensitivity and
spatial resolution [3,7–10]. Since conventional stea-
dy state fluorescence measurements are performed
by integrating fluorescence over a longer time in
comparison with the lifetime of the fluorescence, the
resulting data do not include information of the dy-
namics of the emission process and the effect of de-
polarization on fluorescence due to scattering in
tissues. Some of these issues may be addressed by
performing time-resolved fluorescence depolariza-
tion measurements, which measure the intensity
profile and degree of polarization of fluorescence
within its lifetime, and provide information comple-
mentary to that obtained from steady state spectral
measurements [11].
The use of intrinsic chromophores to differentiate
the optical properties of diseased and healthy human
tissues is limited by their ultraviolet emission bands
[12], which are far from the near-infrared (NIR)
“tissue optical window” [13]. Over the past decade,
Indocyanine Green (ICG, also called Cardio Green),
a clinically approved NIR dye by the US Food and
Drug Administration (FDA), has been investigated
as a contrast agent for optical detection of tumors
[14]. ICG fluoresces in the range of 775nm to 850nm,
which avoids the absorption bands at 950nm and
1195nm due to water, which is the main chromo-
phore component in human tissue in the NIR range
[15,16]. However, ICG is not designed to specifically
target cancer cells. The investigations of receptor ex-
pression in normal and cancer tissues suggest that
small peptide-dye conjugates can be used to target
over-expressed receptors on tumors to enhance spe-
cificity [17]. Biological studies have indicated that
somatostatin receptors (SSTRs), which have five sub-
types, are over-expressed in human prostate tumor
[18]. It was reported that each subtype of somatosta-
tin receptors could be identified on the basis of
molecular modeling of its corresponding peptide con-
jugate [19]. The previous investigation showed that
a small ICG-derivative dye-peptide, cypate-octreote
peptide analogue conjugate (Cytate), could be used
for effectively targeting somatostatin receptor-rich
tumor in the animal model because of the high affi-
nity of Cytate for the somatostatin receptors [20].
In this paper, we report time-resolved fluorescence
and NIR imaging studies for Cytate, an optical con-
trast agent for human prostate cancer detection. The
absorption and fluorescence spectra of Cytate were
measured in the wavelength regions from 650nm
to 900nm and 1100nm, respectively. Time-resolved
fluorescence polarization measurements were per-
formed on Cytate solution and Cytate-stained can-
cerous and normal prostate tissues. Fluorescence
imaging of two small pieces of Cytate-stained normal
and cancerous prostate tissues (one for each) sand-
wiched between large pieces of normal prostate tis-
sues was accomplished.
The experimental data obtained from a Cytate so-
lution were fitted using a time-dependent fluores-
cence depolarization model [21,22]. The resultant
parameters from Cytate fluorescence in solution and
in prostate tissue were compared for understand-
ing the effect of the rotational degree of freedom of
Cytate in a tissue medium. An empirical model
was applied to describe the time-resolved fluores-
cence kinetics and polarization anisotropy of Cytate
in human prostate tissue. The differences of fluores-
cence and image intensities between Cytate-stained
cancerous and normal prostate tissues showed pre-
ferential uptake of Cytate in the former tissue type.
2. Tumor-Targeted Mechanism of Cytate and Its
Absorption and Fluorescence Spectra
Cytate used in this study was prepared by Achilefu’s
group at the Washington University School of Med-
icine. The molecular structure of Cytate is shown in
Fig. 1. It is mainly composed of ICG and the soma-
tostatin receptor ligand, which delivers the ICG to
the receptors presented in the tumor [20]. The synth-
esis of this contrast agent was reported elsewhere
[20]. The advantages of this receptor-targeted pep-
tide-dye contrast agent include enhancing localiza-
tion in tumors, rapid clearance from the nontarget
(normal) tissue, possibility of preparing a library of
peptides for rapid identification of bioactive mole-
cules [20], and keeping the spectral advantages in
Fig. 1. Molecular structure of the cypate-octreote peptide analo-
gue conjugate (Cytate). The part enclosed by a dashed box is ICG
(nonspecific dye without a SSTR ligand). R indicates the molecule
chain of a SSTR ligand.
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the NIR “tissue optical window.” It was reported that
the small ICG-derivative dye-peptide, Cytate, prefer-
entially localized for over 24 hours in tumor with
over-expressed somatostatin receptors in an animal
model [20].
The human prostate is a highly hormone-sensitive
organ. Numerous studies have found that somatosta-
tin is directly or indirectly responsible in the regula-
tion of prostate function [23]. Somatostatin is a small
cyclic peptide. In addition to playing an important
regulatory role of hormones, this peptide controls
cell proliferation in cancerous tissues [18]. Therefore,
tumors arising from somatostatin-needed tissues
frequently express a high density of somatostatin re-
ceptors [24]. Somatostatin receptors are known for
predominant expression in several human adenomas
such as somatotroph and lactotroph adenomas, and
neuroendocrine tumor including human prostate
cancer [18,24,25], and can be used as a basis for
in vivo tumor targeting. Several control experiments
were carried out to determine whether expression of
somatostatin receptors is up regulated in human
prostate malignant cells [26]. Among them, Hansson
et al. have found, by using fluorescing-labeled SSTR
octreotide-binding probes by immunochemical analy-
sis, that SSTR2 and SSTR4 are over-expressed in hu-
man prostate cancerous cells [26]. And Bugaj et al.
have shown that the ligand of Cytate (ICG-derivative
dye-peptide, cypate-octreote peptide analogue con-
jugate) to target somatostatin receptors in animal
model is octreotide [20]. The combination of molecu-
lar probes and optical imaging methods has the po-
tential to provide a better cancer detection technique
with high sensitivity and specificity. The successful
detection of Cytate in somatostatin receptors over-
expressed in tumors in an animal model [20] moti-
vated us to use Cytate to target the over-expressed
specific SSTR2 and SSTR4 in human prostate
cancerous cells. The basis of using Cytate as a pros-
tate cancer contrast agent depends on two factors:
(1) the high affinity of octreotide (ligand of Cytate)
for the somatostatin receptors [20], and (2) the
over-expression of SSTR2 and SSTR4 in human pros-
tate cancer cells [26].
In our spectral study, Cytate was solvated in 20%
aqueous dimethyl sulfoxide (DMSO). The absorption
spectrum of Cytate in DMSO solution was measured
using a Perkin-Elmer Lambda 9 UV/VIS/NIR spec-
trophotometer in the spectral range of 300nm to
900nm. The fluorescence spectrum of Cytate was
measured using a far-red to NIR spectral setup ex-
cited by a 680nm diode laser. Fluorescence emission
from the sample was focused on the entrance slit of a
SPEX Minimate 0:25m monochromator (spectro-
meter) and detected by a Hamamatsu P394A PbS de-
tector mounted at the exit slit of the monochromator.
Signals from the detector were recorded by a PAR
model HR-8 lock-in amplifier connected to a compu-
ter [27].
Figures 2(a) and 2(b) show the measured absorp-
tion and fluorescence emission spectra of Cytate,
respectively. The absorption band of Cytate ranges
from 680nm to 830nm with a shoulder peak at
∼720nm and a strong peak at 789nm. The fluores-
cence spectrum covers from 800nm to 950nm with a
main peak at 837nm and a weak peak at 913nm.
The results show that Cytate possesses the spectral
advantages of ICG, i.e., the fluorescence and the ab-
sorption ranges are in the NIR range of the “tissue
optical window” [27].
3. Experimental Methods for Time-Resolved and
Imaging Measurements
The experimental arrangement for the time-resolved
fluorescence measurements is described in our pre-
vious work [10]. Pulses of 130 fs duration at 800nm
from a Coherent Mira 900 mode-locked Ti:sapphire
laser at a repetition rate of 82MHz were used
to pump the samples (Cytate solution and Cytate-
stained cancerous or normal prostate tissues). The
fluorescence emission was collected by a large dia-
meter lens with a focal length of 5 cm and directed
onto the slit of a synchroscan streak camera with
a temporal resolution of 10ps. A long pass filter
and an 800nm notch filter were used to cut off the
excitation wavelength. Two polarizers, P1 and P2,
were used as a polarizer and an analyzer, respec-
tively. The polarization direction of P2 was varied
Fig. 2. (a) Absorption and (b) fluorescence spectra of Cytate in
20% aqueous DMSO. The fluorescence was obtained with an exci-
tation of a 680nm diode laser beam.
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from 0° to 90° with respect to that of P1 to record the
fluorescence intensity profiles of parallel and perpen-
dicular polarization components of the fluorescence.
The temporal profiles recorded by a silicon intensi-
fied target (SIT) of the streak camera were analyzed
to obtain temporal and polarization information [10].
The Cytate solution used for time-resolved fluores-
cence study was prepared by adding Cytate into 20%
aqueous dimethyl sulfoxide (DMSO). Six cancerous
and six normal prostate tissue samples from six dif-
ferent patients obtained from the National Disease
Research Interchange (NDRI) and the Cooperation
Human Tissue Network (CHTN) were used for the
time-resolved fluorescence and optical imaging mea-
surements under the Institutional Review Board
(IRB) approval at City College of New York (CCNY).
Each cancerous tissue had a corresponding nor-
mal tissue sample from the same patient used for
the control experiment. Samples were neither chemi-
cally treated nor frozen prior to the experiments.
Cancerous and normal prostate tissues used for
the time-resolved fluorescence measurements were
cut into ∼2 cm × ∼1 cm × ∼0:5 cm (length × width ×
thickness) pieces. For each prostate tissue sample,
measurements were performed at six different loca-
tions to get an average value. The cancerous and nor-
mal prostate tissue samples were soaked in the same
Cytate-DMSO (20% aqueous dimethyl sulfoxide) so-
lution with a Cytate concentration of ∼3:2 × 10−6M
for fifteen minutes. Then the samples were put into
sodium phosphate buffer (Sigma-Aldrich) to wash
off the unbound Cytate. All the sample prepara-
tions and measurements were performed at room
temperature.
The schematic diagram of the NIR optical imaging
setup is shown in Fig. 3. A laser beam at 637nm was
used to illuminate the sample. A wide-bandpass
filter at 800nm with a FWHM of 40nm was placed
in front of a CCD camera to record images formed by
light emitted from the sample. A bandpass filter was
used to block the excitation wavelength and to collect
only the light emitted from the sample. The spatial
resolution of the CCD camera is 20 μm=pixel [10].
The prostate tissue samples used for the imaging
measurements consisted of a small piece of cancerous
prostate tissue and a small piece of normal prostate
tissue. They were first soaked in the same Cytate-
DMSO (20% aqueous dimethyl sulfoxide) solution
with a Cytate concentration of ∼3:2 × 10−6M for fif-
teen minutes, and then put into sodium phosphate
buffer to wash off the unbound Cytate. The stained
normal and cancerous prostate tissues were covered
by a large piece of normal prostate tissue as shown in
the sample position of Fig. 3.
4. Experimental Results and Discussion
A. Time-Resolved Fluorescence Polarization Anisotropy of
Cytate in 20% Aqueous DMSO
The measured temporal profiles of the fluorescence
emitted from Cytate in DMSO solution for two po-
larization directions, parallel and perpendicular to
the polarization of the excitation at 800nm, are
shown in Fig. 4(a). The thick- and thin-curve pro-
files represent the parallel ½I‖ðtÞ and perpendicular
½I⊥ðtÞ components, respectively. The time-dependent
polarization anisotropy can be calculated using the
following equation [21,22]:
rðtÞ ¼ I‖ðtÞ − I⊥ðtÞ
I‖ðtÞ þ 2I⊥ðtÞ
: ð1Þ
The thin curve in Fig. 4(b) displays the time evolu-
tion of rðtÞ as calculated. The decay behavior of rðtÞ
reflects the dipole reorientation of Cytate in solvent
since the degree of polarization of the fluorescence
depends on the rotation time and fluorescence life-
time of the molecules [21,22]. If molecular rotation
is much faster compared to the florescence lifetime,
the emitting molecules become randomly oriented
very quickly, resulting in depolarized emission. If
molecules rotate much more slowly in comparison
with the fluorescence decay time, then the emission
remains strongly polarized. Polarization anisotropy
found in our case suggests that rotation time is of
the same order as fluorescence lifetime.
In Fig. 4(a), the main differences between parallel
and perpendicular components are the following:
(1) The intensity of I‖ is greater than that of I⊥ for
all decay times. The peak intensity of the parallel
component I‖ð0Þ is almost three times stronger than
that of the perpendicular component I⊥ð0Þ. This in-
dicates the polarization preservation nature of Cy-
tate. (2) There is a distinct difference between the
decay slopes of the two components, which can be
seen clearly by normalizing the peak of the perpen-
dicular component to that of the parallel component,
as shown by the thin-dashed curve in Fig. 4(a). Since
the rotation time and fluorescence lifetime of Cytate
are on same time scale in our case, the overall decay
time is affected by both reorientation of molecules
and fluorescence decay kinetics. Since the parallel
Fig. 3. Schematic diagram of the optical spectral imaging setup.
The structure of a Cytate-stained cancerous-and-normal prostate
tissue sample covered by a large piece of normal prostate tissue is
shown schematically in the sample position.
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and perpendicular components emitted from Cytate
have same fluorescence lifetime, the fast decay of the
parallel component and slow decay of the perpendi-
cular component are caused by the Cytate molecular
rotation.
In this simple model where Cytate molecules in so-
lution are considered to undergo Brownian rotation
as Einstein spheres, the time-resolved fluorescence
kinetics and polarization anisotropy from Cytate in
aquatic DMSO can be shown as [21,22]







where rð0Þ is anisotropy at t ¼ 0 and τrot is the rota-
tion time of the fluorophore molecule in solvent, de-
termined by the diffusion coefficient, the solvent
viscosity, and the molecular radius [21,22]. The value
of rð0Þ depends on the angle between the absorption
and emission dipoles, and the expectation value of
the second order Legendre polynomial for the distri-
bution function of dipoles [10,28]. The maximum the-
oretical value of rð0Þ is 0.4 [10,21,22,28].
The experimental value of rð0Þ obtained from the
data shown in Fig. 4(b) is ∼0:33, which is in reason-
able agreement with the theoretical value of 0.4
[21,22]. As mentioned by Flemming [21] and Porter
[22], the measured value of rð0Þ is always smaller
than its theoretical value due to (1) the rapid internal
motions of the macromolecules, since the macro-
molecules must contain a flexible substructure that
can undergo rapid depolarization rotation, (2) scat-
tering of light in tissues, and (3) birefringence of
the quartz cell containing the samples. This result
indicates that the transition dipole moments of Cy-
tate molecules in solution are randomly oriented,
and the depolarization effects of Cytate in 20% aqu-
eous DMSO solvent can be confined to molecular
rotations and to the trivial effect of initial random-
ness [21]. The polarization anisotropy peak value,
rð0Þ, and the rotation time,τrot, of Cytate in solution
can be obtained by fitting the experimental data of
rðtÞ shown in Fig. 4(b) using Eq. (2). The best fit
was obtained with the parameter values of rð0Þ ¼
0:337 0:032 and τrot ¼ 352 21ps, and the fitting
curve is shown by the thick-dark curve in Fig. 4(b).
B. Time-Resolved Fluorescence Polarization Anisotropy
of Cytate Contained in Stained Cancerous and Normal
Prostate Tissues
Six Cytate-stained cancerous and six Cytate-stained
normal prostate tissue samples from six patients
were used for the time-resolved fluorescence mea-
surements. For each sample, measurements were
performed on six or more different locations for sta-
tistical analysis. Before the measurements were per-
formed, the tissue sample was carefully checked to
determine the hard parts to locate the small region
of the cancerous tissue. This is acknowledged to be a
simple way to find the location of malignancy [29].
Two typical time-resolved fluorescence intensity
profiles for the cancerous and normal prostate tis-
sue samples stained with Cytate are displayed in
Fig. 5(a). The thick-solid and thick-dashed curve pro-
files represent the parallel and the perpendicular
components of emission from stained cancerous tis-
sue, respectively. The thin-solid and thin-dashed
curve profiles display the parallel and perpendicular
components of emission from stained normal tissue,
respectively.
One of the most important features of the pro-
files in Fig. 5(a) is the higher emission intensity
of the stained cancerous tissue compared to the
stained normal tissue throughout the Cytate emis-
sion range. Using the data in Fig. 5(a), for the
Fig. 4. Temporal polarization profiles and polarization anisotro-
py of light emitted from Cytate in 20% aqueous DMSO with a po-
larized 800nm laser illumination. (a) Profiles of the time-resolved
fluorescence components having polarization directions parallel
(thick curve) and perpendicular (thin curve) to the polarization di-
rection of the exciting light. The thin-dashed curve displays the
normalized perpendicular components. (b) Time-dependent polar-
ization anisotropy (thin curve) calculated using the measured data
shown in (a) and Eq. (1) shown in the text, and the fitting curve
(thick curve) calculated using Eq. (2) shown in the text and the
data shown by the thin curve in Fig. 5(b).
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parallel polarization configuration, the ratio of peak
fluorescence intensity of the Cytate-stained cancer-
ous tissue to that of the normal tissues was found
to be ∼3:57, while for the perpendicular configura-
tion, the ratio was ∼3:25. These ratios indicate that
cancerous prostate tissue has higher Cytate intake
than normal tissue.
Another important feature of the temporal profiles
is that I‖ is greater than I⊥ throughout the decay
period for both cancerous and normal tissues. At
the peak position, Icancer
‖
ð0Þ is ∼1:60 times stronger
than Icancer
⊥





ð0Þ is ∼1:46. This indicates that the fluores-
cence emitted from both Cytate-stained cancerous
and normal prostate tissues show the polariza-
tion preservation property, although the ratio of
I‖ð0Þ=I⊥ð0Þ is smaller than that of Cytate solution.
Using Eq. (1) and the measured values of I‖ðtÞ and
I⊥ðtÞ shown in Fig. 5(a), the temporal profiles of
the polarization anisotropy rðtÞ from Cytate in
stained cancerous (thin-solid curve) and normal
(thin-dashed curve) prostate tissues were calculated,
and the results are displayed in Fig. 5(b).
The interesting features of rðtÞ curves shown in
Fig. 5(b) are the following: (1) the profiles of Cytate-
stained tissue show a flatter decay compared to that
of Cytate solution; and (2) the values of the polariza-
tion anisotropy of Cytate in the stained cancerous tis-
sue are always larger than that of the stained normal
tissue. The peak intensity values of rð0Þ for cancer-
ous and normal tissues were found to be rð0Þcancer ¼
0:167 0:021 and rð0Þnormal ¼ 0:133 0:011, pre-
sented as mean values  standard deviations. These
results indicate that the Cytate-stained cancerous
tissue shows a better polarization preservation prop-
erty than the Cytate-stained normal prostate tissue.
The polarization preservation properties of Cytate-
stained prostate tissue can be used to enhance the
image contrast between cancerous and normal pros-
tate tissue areas combining with a fluorescence-
polarization-difference imaging (FPDI) technique
[10,27,30].
The value of rð0Þ for a dye solution depends on the
viscosity of the solvent [28]. Above a critical value of
the viscosity of about 3000 poise, a normalized orien-
tation distribution function was used as a model for
fluorescent molecules instead of random distribution
[28]. By applying this distribution function, a value of
rð0Þ ¼ 0:1039 was calculated for the condition of the
viscosity greater than 3000 poise [10,28]. It was also
reported that biological living tissue might mimic the
behavior of viscous liquids [31]. The viscosities of
biological tissues, including prostate tissue, were re-
ported to be much higher than 3000 poise [32]. If the
case of Cytate in prostate tissue is considered as a
fluorescent dye in a “very high viscosity liquid,”
the anisotropy rð0Þ should be expected to be in the
range between ∼0:10 and ∼0:12.
The physical model generated from our previous
study [10] on cybesin (another NIR contrast agent
used to target bombesin receptor that is also over-
expressed in prostate tumors) suggests that the
time-resolved fluorescence polarization anisotropy
rðtÞ of the emission from NIR fluorescent dye con-
tained in stained human prostate tissues can be
considered to have two components: (1) a static ani-
sotropy component caused by the emission from
the tissue cell-bonded Cytate molecules without rota-
tion; and (2) a time-dependent anisotropy component
formed by the emission from the unbound Cytate
Fig. 5. (a) Time-resolved fluorescence intensity of light emitted
from Cytate-stained cancerous and normal prostate tissues with
800nm laser illumination. The thick-solid and thick-dashed curve
profiles are the parallel and perpendicular components emitted
from Cytate-stained cancerous prostate tissue, respectively. The
thin-solid and thin-dashed curve profiles display the parallel
and perpendicular components emitted from Cytate-stained nor-
mal prostate tissues, respectively. (b) Time-dependent polarization
anisotropy calculated using Eq. (1) shown in the text and the mea-
sured data shown in Fig. 5(a). The thin-solid and thin-dashed
curve profiles indicate the rðtÞ for Cytate-stained cancerous and
normal prostate tissues, respectively. The fitting curves for Cytate
in cancerous prostate tissue (thick-solid curve) and Cytate in nor-
mal prostate tissue (thin-solid curve) were calculated using Eq. (3)
shown in the text and the corresponding polarization anisotropy
shown in Fig. 5(b).
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molecules with rotation in the body fluid of prostate
tissue [10]. These assumptions are reasonable be-
cause a tissue cell is too massive to rotate compared
to a Cytate molecule. This empirical model was de-
veloped to describe the time-resolved fluorescence ki-
netics and polarization anisotropy emitted from
contrast agent stained tissues [10]. Using this model,
the temporal fluorescence polarization anisotropy
rðtÞ of Cytate contained in stained prostate tissues
can be described by





where r0 expð−t=τrotÞ is the time-dependent portion of
the polarization anisotropy induced by the “free”
Cytate molecules in the fluid of prostate tissue, τrot
is the rotation time of the “free” Cytate in prostate
tissue, rð0Þ is the peak value of the polarization ani-
sotropy of the “free” Cytate molecules, and r1 is the
static portion of the polarization anisotropy induced
by the cell-bond Cytate molecules in prostate tissue.
The three parameters τrot, r0, and r1 can be obtained
by fitting the experimental data of rðtÞ shown in
Fig. 5(b) using Eq. (3).
The best fitting curves for Cytate-stained cancer-
ous (thick-solid curve) and normal (thin-solid curve)
prostate tissues are shown in Fig. 5(b). The fitting
results yielded the following parameters: r0 ¼
0:115 0:012, τrot ¼ 900 180ps, and r1 ¼ 0:062
0:013 for Cytate in stained cancerous prostate tissue,
and r0 ¼ 0:109 0:030, τrot ¼ 550 140ps, and r1 ¼
0:014 0:004 for Cytate in stained normal tissue.
These values are in reasonable agreement with
our experimental data.
The fitting results yield that rcancer1 > r
normal
1 . This
can be understood from the fact that the perpendicu-
lar component of the fluorescence emitted from cell-
bond Cytate molecules is mainly contributed by the
photons undergoing multiple scattering [10,30].
Since the excitation wavelength of 800nm is close
to the strong absorption peak of Cytate and cancer-
ous prostate tissue has higher Cytate intake than
normal tissue, the stained cancerous tissue region
would absorb more photons than the stained normal
tissue regions. Light from the same excitation source
would go deeper in normal prostate tissue than in
cancerous tissue. As a result, the fluorescence from
normal prostate tissue comes from the Cytate mole-
cules embedded in deeper tissue layers than the Cy-
tate molecules in the cancerous prostate tissue [10].
The light emitted from the stained cancerous tissue
area undergoes less multiple scattering than that
from the stained normal tissue. As a result, the de-
gree of polarization and the value of r1 for the stained
cancerous tissue region are much larger than that of
the stained normal tissue region [10].
The fitting results also show that τcancerrot > τnormalrot .
The larger decay time of free Cytate molecules in
cancerous prostate tissue indicates the higher local
viscosity of cancerous prostate tissue due to high
density and decreasing interstitial spacing between
cells. The higher density of cancerous cells can be re-
cognized by the nature of evolution of a malignant
tumor [29]. First the tumor grows in volume; when
it reaches some kind of confining volume, the me-
chanical pressure increases its cell density. When the
tumor cell density exceeds a certain compaction max-
imum, invasion starts [29,33]. The tumor grading
system for prostate cancer includes the well known
five Gleason grades, usually denoted as stages 1–5
[34]. The pattern of Gleason grade 1 (corresponding
to early stage) consists of a circumscribed mass of
evenly placed uniform glands. With grade advances,
the cancer cells proliferate and begin to merge into
an “island” [34]. This pattern appears at grade 3
and is obvious at grade 5 [34]. The microscopic his-
tological images shown in our previous work [27] also
indicate the “island” structure and high density of
cancerous cell. The higher cell density in cancerous
prostate tissue [29,33,34] gives the molecules less
“free” rotation space [10,29,34]. In addition, the
dye crowds more in cancerous tissue due to higher
adsorption levels of bound Cytate as shown by the
larger emission intensity in Fig. 5(a). The crowding
dye chains form a compact or contracted coil in which
the dye is embedded [35]. This effect increases the
local viscosity [35], which in our view is the reason
behind the larger decay time of Cytate in cancerous
prostate tissue compared to that in normal prostate
tissue samples.
5. Optical Imaging
To study the potential of Cytate for prostate cancer
detection by NIR imaging, cancerous-and-normal
prostate tissue samples were imaged using a NIR
spectral imaging system. In order to image a hidden
tissue, a small piece of cancerous prostate tissue and
another small piece of normal prostate tissue stained
with Cytate were sandwiched between two large
pieces of prostate normal tissue with a thickness
of∼1mm for the front piece. The fluorescence images
of the Cytate-stained prostate tissues were recorded
at 800nm by exciting at 637nm. Figure 6(a) shows
recorded NIR images of the stained cancerous and
normal prostate tissues embedded underneath the
∼1mm thick normal prostate tissues. As displayed
in Fig. 6(a), the emission intensity of the Cytate-
stained cancerous tissue is higher than that of the
Cytate-stained normal tissue.
This property of preferential uptake of Cytate by
cancerous prostate tissue can be more clearly visua-
lized by Fig. 6(b), which is the digital spatial cross
section of intensity distribution of the image shown
in Fig. 6(a). Using the digital data shown in Fig. 6(b),
the ratio of imaging intensity of the cancerous tissue
area to that of normal tissue area is found to be
∼3:54. To compare the results of the imaging mea-
surements with that of time-resolved fluorescence
experiments, peak intensities of I‖ and I⊥ for both
cancerous and normal tissue shown in Fig. 5(a) were
added, and the ratio of peak fluorescence intensities
emitted from Cytate-stained cancerous tissue to that
1 May 2008 / Vol. 47, No. 13 / APPLIED OPTICS 2287
from the normal tissue was calculated to be ∼3:45.
This value obtained from the time-resolved fluo-
rescence measurements is in a good agreement
with that obtained from the spectral imaging
measurements.
Both fluorescence intensity measurements and op-
tical spectral imaging study show the preferential
uptake of Cytate by prostate cancerous tissue. Since
Hansson et al. reported that the over-expressed
SSTR2 and SSTR4 on prostate tumor cells bind oc-
treotide [26], and the ligand of Cytate to target soma-
tostatin receptors in animal model is octreotide [20],
we may infer that Cytate achieved targeting the
over-expressed specific SSTR2 and SSTR4 in human
prostate cancerous cells.
6. Conclusion
Steady state absorption- and fluorescence-spectral
measurements were performed on Cytate, a cancer
receptor-targeted contrast agent, to study its via-
bility in cancer detection. Time-resolved fluorescence
kinetics and polarization anisotropy of Cytate in so-
lution and in stained human cancerous and normal
prostate tissues were investigated. The experimental
results show a larger degree of polarization preser-
vation of fluorescence from Cytate in the stained
cancerous tissue than in the stained normal tissue.
The fluorescence intensity emitted from the Cytate-
stained cancerous prostate tissue was found to be
much stronger than that from the Cytate-stained
normal prostate tissue indicating that cancerous
prostate tissue has a higher Cytate intake than nor-
mal tissue. The time-resolved fluorescence intensity
profile from a Cytate solution was fitted using a time-
dependent fluorescence depolarization model. An
empirical physical model was applied to describe the
behavior of fluorescence kinetics and polarization an-
isotropy of Cytate in stained cancerous and normal
prostate tissues. Optical imaging of cancerous and
normal prostate tissues stained with Cytate was per-
formed. The fluorescence image of the Cytate-stained
cancerous prostate tissue region was found to be
much brighter than that of the Cytate-stained nor-
mal tissue region. Cytate was shown to be an excel-
lent contrast agent because its absorption and
fluorescence spectra lie in the NIR “tissue optical
window.” Both fluorescence intensity and optical
imaging studies show the potential of Cytate as a
fluorescent marker in prostate cancer detection.
7. Future Work
Further biomedical studies are needed to follow up
this spectral and optical imaging investigation. Some
immunochemical analysis is needed to identify the
somatostatin receptor subtypes that are targeted
by Cytate. Experiments for quantifying the differ-
ence in the number of somatostatin receptors be-
tween cancerous and normal prostate tissues need
to be performed and compared for different Gleason
grades. Some biomedical work is needed to study the
transport of Cytate across the cell membrane and
into the cell cytoplasm, and to see whether 20%
DMSO concentration of aqueous solution has any ad-
verse effect on tissue.
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Fig. 6. (a) Contrast agent fluorescence image of a cancerous-and-
normal prostate tissue sample (a tiny piece of Cytate-stained can-
cerous prostate tissue and a tiny piece of Cytate-stained normal
prostate tissue covered by a large piece of normal prostate tissue).
(b) Digital spatial cross section intensity distribution of the image
shown in Fig. 6(a) at a row crossing the areas of the stained cancer
(C) and normal (N) tissues.
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